R406, an Orally Available Spleen Tyrosine Kinase Inhibitor Blocks Fc Receptor Signaling and Reduces Immune Complex-Mediated Inflammation

  title={R406, an Orally Available Spleen Tyrosine Kinase Inhibitor Blocks Fc Receptor Signaling and Reduces Immune Complex-Mediated Inflammation},
  author={Sylvia Braselmann and Vanessa C. Taylor and Haoran Zhao and Suizhao Wang and Catherine Sylvain and Muhammad Baluom and Kunbin Qu and Ellen Herlaar and Angela Lau and Chi Young and Brian R. Wong and Scott Lovell and Thomas Sun and Gary Park and Ankush B. Argade and Stipo Jurcevic and Polly R. Pine and Rajinder Singh and Elliott B. Grossbard and Donald G. Payan and Esteban S. Masuda},
  journal={Journal of Pharmacology and Experimental Therapeutics},
  pages={1008 - 998}
Recent compelling evidence has lead to renewed interest in the role of antibodies and immune complexes in the pathogenesis of several autoimmune disorders, such as rheumatoid arthritis. These immune complexes, consisting of autoantibodies to self-antigens, can mediate inflammatory responses largely through binding and activating the immunoglobulin Fc receptors (FcRs). Using cell-based structure activity relationships with cultured human mast cells, we have identified the small molecule R406 [N4… 

Figures and Tables from this paper

A Novel Triazolopyridine-Based Spleen Tyrosine Kinase Inhibitor That Arrests Joint Inflammation
CC-509 is a potent, moderately selective, and efficacious inhibitor of Syk that has a differentiated profile when compared to other Syk compounds that have progressed into the clinic for RA.
Specific Inhibition of Spleen Tyrosine Kinase Suppresses Leukocyte Immune Function and Inflammation in Animal Models of Rheumatoid Arthritis
Specific Syk inhibition can mimic Syk genetic deficiency to modulate immune function, providing a therapeutic strategy in P505-15 for the treatment of human diseases.
The active metabolite of spleen tyrosine kinase inhibitor fostamatinib abrogates the CD4⁺ T cell-priming capacity of dendritic cells.
Findings indicate a potential mechanism by which this compound may be effective in inhibiting FcR-driven CD4(+) T cell responses.
TAS05567, a Novel Potent and Selective Spleen Tyrosine Kinase Inhibitor, Abrogates Immunoglobulin-Mediated Autoimmune and Allergic Reactions in Rodent Models
Data indicate TAS05567 is a selective Syk inhibitor and potential therapeutic candidate for treating humoral immune-mediated inflammatory conditions such as autoimmune and allergic diseases.
Targeting Spleen Tyrosine Kinase-Bruton's Tyrosine Kinase Axis for Immunologically Mediated Glomerulonephritis
Recent studies of Syk and Btk inhibitors in several experimental primary and secondary glomerulonephritis models suppressed development of glomerular injury, and also ameliorated established kidney disease.
Molecular targets on mast cells and basophils for novel therapies.
BI 1002494, a Novel Potent and Selective Oral Spleen Tyrosine Kinase Inhibitor, Displays Differential Potency in Human Basophils and B Cells
The data provide a platform from which different estimates of human efficacious exposures can be made according to the relevant cell type for the indication intended to be treated, and SYK inhibitors may exhibit differential potency depending on the cell type and the respective signal transduction ligand.


The Orally Available Spleen Tyrosine Kinase Inhibitor 2-[7-(3,4-Dimethoxyphenyl)-imidazo[1,2-c]pyrimidin-5-ylamino]nicotinamide Dihydrochloride (BAY 61-3606) Blocks Antigen-Induced Airway Inflammation in Rodents
It was demonstrated that Syk may play a very critical role in the pathogenesis of allergic reactions and was identified as a potent and selective inhibitor of Syk kinase.
A Novel Spleen Tyrosine Kinase Inhibitor Blocks c-Jun N-Terminal Kinase-Mediated Gene Expression in Synoviocytes
It is demonstrated that Syk activation plays an essential role in TNFα-induced cytokine and matrix metalloproteinase production in RA FLS, especially by suppressing activation of the JNK pathway.
Targeting Syk as a treatment for allergic and autoimmune disorders
Syk is an intracellular protein tyrosine kinase that was discovered 15 years ago as a key mediator of immunoreceptor signalling in a host of inflammatory cells including B cells, mast cells, macrophages and neutrophils and thus pharmacologically interfering with Syk could conceivably treat these disorders.
Inhibition of spleen tyrosine kinase prevents mast cell activation and airway hyperresponsiveness.
A functional role for Syk is delineated in the development of mast cell- and IgE-mediated AHR and airway inflammation, and these results indicate that inhibition of Syk may be a target in the treatment of allergic asthma.
Identification of the Syk kinase inhibitor R112 by a human mast cell screen.
A dominant role for mast cell Fc receptors in the Arthus reaction.
IgG Fc receptors.
Fc gamma Rs offer a paradigm for the biological significance of balancing activation and inhibitory signaling in the expanding family of activation/inhibitory receptor pairs found in the immune system.
Arthritis critically dependent on innate immune system players.
Impaired IgG-Dependent Anaphylaxis and Arthus Reaction in FcγRIII (CD16) Deficient Mice
Fcγ Receptors: Old Friends and New Family Members